The Future Of Purdue: Will The ‘Public Benefit Corporation’ Model Take Off?

 
• By Michael McCaughan

Purdue’s opioid settlement is making headlines for the size of the financial penalty. But the plan to re-imagine Purdue as a ‘public benefit company’ could have far-reaching significance for the industry – if it ever gets off the ground.

The headquarters of Purdue Pharma is shown on September 16, 2019 in Stamford, Connecticut. (Photo by John Moore/Getty Images)
Purdue's headquarters in Stamford, CT, shown here in 2019. The firm could emerge from bankruptcy as a Public Benefit Corporation. • Source: John Moore/Getty Images

The headlines surrounding Purdue’s landmark settlement of opioid marketing investigations are understandably focusing on the dollars involved.

At $8 billion-plus, the settlement announced by the US Department of Justice on 21 October is simultaneously massive – and already subject to complaints from other prosecutors and advocates that...

More from Pricing Debate

More from Market Access